Extended follow-up of patients with hairy cell leukemia after treatment with cladribine

Journal of Clinical Oncology

Volumn 21, Issue 5, 2003, Pages 891-896

  Goodman, Grant R ^b   Burian, Carol ^b   Koziol, James A ^b   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; PENTOSTATIN; ANTINEOPLASTIC AGENT; INTERFERON;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SECOND CANCER; SPLENECTOMY; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MORTALITY; PATHOLOGY; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERONS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PENTOSTATIN; REMISSION INDUCTION; SPLENECTOMY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037362951     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.05.093     Document Type: Article

References (23)

1. Bouroncle BA, Wiseman BK, Doan CA: Leukemic reticuloendotheliosis. Blood 13:609-630, 1958
2. Grever M, Kopecky K, Foucar MK, et al: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 13:974-982, 1995
3. Tallman MS, Hakimian D, Rademaker AW, et al: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: Long-term follow-up of the Northwestern University experience. Blood 88:1954-1959, 1996
4. Saven A, Piro L: Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 330:691-697, 1994
5. Piro LD, Carrera CJ, Carson DA, et al: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117-1121, 1990
6. Saven A, Burian C, Koziol JA, et al: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918-1926, 1998
7. Carson DA, Wasson DB, Kaye J, et al: Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci U S A 77:6865-6869, 1980
8. Robertson LE, Plunkett W: Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma 11:71-77, 1993 (suppl)
9. Saven A, Burian C, Adusumalli J, et al: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93:2471-2477, 1999
10. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
11. Ries LA, Miller BA, Hankey BF, et al (eds): SEER Cancer Statistics Review, 1973-1991: Tables and Graphs, National Cancer Institute. National Institute of Health Publication No. 94-2789. Bethesda, MD, National Cancer Institute, 1994
12. Hoffman MA, Janson D, Rose E, et al: Treatment of hairy-cell leukemia with cladribine: Response, toxicity, and long-term follow-up. J Clin Oncol 15:1138-1142, 1997
13. Cheson BD, Sorensen JM, Vena DA, et al: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: A report of 979 patients. J Clin Oncol 16:3007-3015, 1998
14. Mackowiak PA, Demian SE, Sutker WL, et al: Infections of hairy cell leukemia: Clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 68:718-724, 1980
15. Ruco LP, Procopio A, Maccallini V, et al: Severe deficiency of natural killer activity in the peripheral blood of patients with hairy cell leukemia. Blood 61:1132-1137, 1983
16. Cheson BD, Vena DA, Barrett J, et al: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454-2460, 1999
17. + lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906-2911, 1994
18. Au WY, Klasa RJ, Gallagher R, et al: Second malignancies in patients with hairy cell leukemia in British Columbia: A 20-year experience. Blood 92:1160-1164, 1998
19. Kurzrock R, Strom SS, Estey E, et al: Second cancer risk in hairy cell leukemia: Analysis of 350 patients. J Clin Oncol 15:1803-1810, 1997
20. Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981-2986, 2000
21. Kraut EH, Grever MR, Bouroncle BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2′-deoxycoformycin. Blood 84:4061-4063, 1994
22. Nieva J, Bethel K, Baker T, et al: Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 98:364a, 2001 (abstr)
23. Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241-247, 2001